Laboratory diagnosis of megaloblastic anaemia: current methods assessed by external quality assurance trials

D W DAWSON,* D I FISH,* I D O FREW†, T ROOME†, I TILSTON†

From the Department of *Haematology, North Manchester General Hospital, Manchester, and †Good Hope Hospital, Sutton Coldfield, West Midlands

SUMMARY The results of an Interregional quality assurance scheme for tests in the diagnosis of megaloblastic anaemia were reviewed to assess the methods used. Serum folate assays showed great variation between methods, partly due to limitations in assessment by external quality assurance. Red cell folate assays yielded widely different results and much imprecision due both to the differences in preparation of the haemolysate and to the problems inherent in radioassay of a mixture of folate compounds. Intrinsic factor antibody tests showed appreciable variation in sensitivity. There was considerable inconsistency in the detection of polymorph nuclear hypersegmentation.

Regional trials in haematology provide laboratories with external quality assurance. We have organised a scheme for vitamin assays for some years,¹ adding two other tests more recently. The number of participants, however, permits not only an assessment of individual performance but also of the methods in use. The results of the trial give an indication of current practice.

TRIALS

Vitamin assays

Two samples are issued 11 times yearly for serum vitamin B12 and folate assays with a whole blood specimen in CPD-adenine for red cell folate assays. An arbitrary haematocrit of 0.45 and serum folate of 1.0 µg/l were given with the whole blood sample. Table 1 shows the methods and the present number of laboratories making returns with them (in parentheses). On average, 90% of participants report vitamin B12 results, and 86% folate results. We recorded only those results which reflected the performance of the assay methods in routine practice, omitting those using materials other than serum and whole blood.

The relative accuracy of vitamin B12 methods was compared by taking the microbiological assay results and regarding their mean in each trial as 100%. For

serum and red cell folate assays, the results by *Lactobacillus casei* were taken to be 100%. Truncation, depending on the number of returns,² was applied to each method mean. Precision after truncation was determined when there were five or more returns for a method. Participants interpreted their results as low, indeterminate, normal, or high.

A secondary liquid reference serum, standardised against the British standard for human serum vitamin B12, assigned a value of 355 (338-372) ng/l by our radioisotopic non-commercial assay, was distributed as an unknown serum in a recent trial.

Intrinsic factor antibody (IFA) tests

On two occasions pooled pernicious anaemia serum,

Table 1 *Methods currently used and No of laboratories making return*

	Vitamin B12	Folate
<i>Lactobacillus leichmannii</i>	9	
<i>Euglena gracilis</i>	2	
<i>Lactobacillus casei</i>		4
Chloramphenicol-resistant <i>Lactobacillus casei</i>		12
Radioisotopic non-commercial	9	1
Amersham	20	19
Becton Dickinson	117	117
Biorad	6	7
Micromedic	14	15
Corning	6	4
Diagnostic Products	3	3

control serum, and one or more dilutions of one in the other were issued.

Polymorph neutrophil hypersegmentation

Stained blood films were sent out on two occasions: on the first, brief details of the patient were given—mild macrocytosis without anaemia and equivocal vitamin assays. On the second, a blood film from the same patient after three months of treatment with folic acid, which reduced the mean cell volume to normal, and a film from a patient with early pernicious anaemia were distributed without any clinical data. A yes or no answer was requested to the question, "is hypersegmentation present?", together with a score if this was the laboratory custom.

Results

VITAMIN B12 ASSAYS

Accuracy

Fifty issues of normal sera had been made during the period under review. Table 2 shows the annual mean concentrations by each method as a percentage of the microbiological mean. The average of all methods was close to that of the reference methods, and most differences were consistent. The number of users of each method varied considerably, but the overall average was not noticeably affected by weighting each method result by the number within it. The grand mean of the secondary reference preparation from 176 participants was 361 ng/l. The number using the solid phase Becton Dickinson kits permitted separate analysis of their performance in recent trials (table 3). With five normal sera the solid phase means were higher than the solid phase no-boil and the liquid Simultrac means. The differences between the liquid

and solid phase were significant at the 5% level with four sera, and between solid phase and solid phase no-boil, with three sera by unpaired *t* tests. With two pernicious anaemia sera the solid phase and liquid system means were similar and the solid phase no-boil means lower.

Sera spiked with cobinamide (10 µg/l) were issued three times. An excessive increment over the untreated sample result was no more common than may have arisen from imprecision.

Interpretation

With five pernicious anaemia sera there were 44 "normal" returns from 193 assays. The incidence did not correlate with method, except that it was most common with radioisotopic non-commercial in the earlier years, and for all methods it was inversely related to the mean vitamin B12 concentration; there were no errors by Euglena. Five of the 44 errors were clerical.

Precision

There was steady improvement in precision from an average coefficient of variation (CV) for all methods of 20.7% in 1982 to 15.1% in 1985. Table 4 shows the method means from the results of 17 assays of normal sera in 1985.

SERUM FOLATE ASSAYS

Relative accuracy

The differences in the annual means of the methods have been fairly consistent over the last four years. Chloramphenicol resistant *L. casei*, except during a period in 1982, was higher, Amersham, Becton Dickinson, and Micromedic were lower, and Biorad, Cor-

Table 2 *Relative accuracy of serum vitamin B12 assays*

Year	Radioisotopic non-commercial	Amersham	Becton Dickinson	Biorad	Micromedic	Corning	Diagnostic Products	Mean
1982	105	93	98	105		108		102
1983	98	87	96	95	117	102		99
1984	99	86	96	104	111	106		100
1985	101	90	93	100	107	95	92	97
Mean	101	89	96	101	112	103	92	99

Table 3 *Assays with three Becton Dickinson kits*

	Liquid system	Solid phase	solid phase no-boil
Serum vitamin B ₁₂ (ng/l)			
5 normal	367 (456)	394 (84)	373 (35)
2 pernicious anaemia	88 (169)	87 (28)	49 (12)
Serum folate (µg/l)	3.5 (436)	3.6 (90)	4.2 (37)
Red cell folate (µg/l)	217 (460)	160 (59)	198 (36)
% reported subnormal	12	53	9

Laboratory diagnosis of megaloblastic anaemia

ning, and diagnostic products were close to the *Lactobacillus casei* mean each year. Table 5 shows the results from 1985, together with the results of two recovery experiments.

With Becton Dickinson liquid and solid phase systems the results were close to each other and the solid phase in-boil system higher (table 3).

Precision

The average CV for the kit methods in each trial has decreased by 5% during the past four years to 18%, whereas that of chloramphenicol resistant *L casei* has worsened by 3%. Table 4 shows the average annual CVs for normal sera during 1985.

RED CELL FOLATE ASSAYS

Relative accuracy

Table 5 shows the relative means, as a percentage of *Lactobacillus casei* (100%), from assay of normal samples during 1985. Overall, the annual kit means have decreased from 136 to 114% in the past three years, with the greatest reduction from 157 to 73% by Biorad. Amersham and Corning showed little change during this period.

Table 3 shows the results with three samples by Becton Dickinson kits. The differences between the liquid and solid phase were significant with each sample.

Precision

Table 4 shows the means of the trial CVs during 1985 for methods with eight or more participants.

INTRINSIC FACTOR ANTIBODY (IFA) TESTS

Thirty five laboratories did these tests. Two issues of

sera were made with 29 returns from the first and 26 from the second. The first issue was of three sera (one normal), the second a pool of pernicious anaemia sera, and the third a mixture of both to give a low antibody titre. All participants recorded the first negative and the second positive. In the second trial a strongly positive serum and $\times 10$, $\times 20$, and $\times 40$ dilutions of it in normal serum were issued. Twenty of the 25 tests on the neat and $\times 10$ and $\times 20$ dilutions were found to be positive, and all but one laboratory found the normal serum negative. Table 6 combines the results of the tests on the $\times 40$ dilution and the third serum of the first trial, and these are listed according to method. The incidence of positive results in the home brew group, according to method, were two of 15 (Gottlieb *et al*³), two of six (Ardeman and Chanarin⁴), three of eight (Ghazi⁵), and one of one (Conn⁶). Seven laboratories recorded antibody concentration ranging from 2.0 to 21.3 (median 9.8), 1.0 to 7.1 (median 4.3), and 0 to 3.5 (median 2.0) units/ml with the $\times 10$, $\times 20$, and $\times 40$ dilutions, respectively, of the positive serum.

POLYMORPH NEUTROPHIL HYPERSEGMENTATION

Sixty three of the 90 replies to the first issue were affirmative. Table 7 shows the 137 replies to slide 2, from the same patient after folic acid treatment, and to slide 3, from the patient with pernicious anaemia. The 98 negatives to slide 2 and 100 positives to slide 3 were consistent with the clinical data: 50% reported both correctly; 23% showed a positive bias; 21% a negative bias.

Discussion

Seven assessments of the currently used kits for vitamin B12 and folate assays have been reported.⁷⁻¹⁰

Table 4 Average trial of CVs % for precision

	<i>Lactobacillus casei</i>	Chloramphenicol resistant <i>L casei</i>	Radioisotopic non-commercial	Amersham	Becton Dickinson	Micromedic
Vitamin B12	19.9 (9)		18.1 (8)	12.5 (19)	14.3 (103)	10.6 (13)
Serum folate		20.7 (11)		24.4 (18)	16.7 (97)	15.0 (15)
Red cell folate		25.7 (11)		34.9 (16)	34.8 (91)	21.4 (11)

Figures in parentheses represent average number of returns per trial analysed after truncation.

Table 5 Folate assays

	<i>Lactobacillus casei</i>	Chloramphenicol resistant <i>L casei</i>	Amersham	Becton Dickinson	Biorad	Micromedic	Corning	Diagnostic products
Mean of assays of 13 sera compared with <i>Lactobacillus casei</i> (100% = 4.4 µg/l)	100	114	50	81	98	87	104	96
Percentage recovery of 5.0 µg/l folic acid added to 2 sera	106	106	94	94	94	70	87	95
Means of assays of 12 whole blood samples compared with <i>Lactobacillus casei</i> (100% = 204 µg/l)	100	94	155	111	73	131	90	135

Table 6 Results with two sera for intrinsic factor antibody tests

Method	Positive	Indeterminate	Negative
Non-commercial	8	2	21
Becton Dickinson kit reagents	5	1	0
Corning	3	5	2
Diagnostic products	6	1	1

Table 7 Neutrophil hypersegmentation: replies to questionnaire

		Slide 2	
		No	Yes
Slide 3	Yes	69	31
	No	29	8

A full evaluation of even only two or three requires much time, has usually to be limited to only a few different batches, and will show the method under the most ideal conditions. The results from quality assurance schemes can supplement kit assessments, indicating the performance over a period of time in a variety of laboratories.

Radioisotope assays of vitamin B12 assays have improved considerably since our previous review.¹ The most important change has been in their relative accuracy. The differences between kits has narrowed, and the mean produced by all participants can now be taken as close to the "true" value, as determined by the chosen reference method, when normal sera are assayed. It would be unwise to assume that the convergence of means would also apply at lower levels, though all kits used in the trials in the past four years differentiate pernicious anaemia sera from normal. A comparison of many methods¹¹ showed that all were capable of distinguishing normal from abnormal sera, providing that the user's own reference range was considered.

The secondary reference serum preparation, which will be checked periodically against the British primary standard, is now available to all trial participants. We would encourage any laboratory to produce its own normal serum pool, standardised against the secondary preparation.

The assay of serum folate has not shown the same improvement. The differences in relative accuracy have been fairly constant over the past four years (diagnostic product not included before 1985), though precision has improved. The means by Amersham are considerably lower than the others though the manufacturer's reference range is not. We do not now add ascorbic acid to the issued sera because of their simultaneous use for vitamin B12 assays, but when we did before 1985, similar differences were observed.

Not only have the Amersham means been lower but the incidence of interpretations as subnormal have been higher. An average 95% recovery was obtained from the addition of folic acid to ascorbate treated sera on three occasions. Amersham International PLC recognise the production of low results with quality assurance materials, consider it to be due to oxidation of methylfolate, and offer a modified protocol (addition of dithiothreitol) for testing these. The other kits provide the reducing agent for routine use. Lower folic acid recovery was found with Micromedic and Corning, the two kits with methylfolate standards.

The *Lactobacillus casei* method was chosen as the assay against which the others were compared, though it contained a decreasing number of participants. Comparison with chloramphenicol resistant *L casei* would have shown even greater differences for most methods. Chloramphenicol resistant *L casei* means have been regularly higher than *lactobacillus casei* means, except for a period in 1982.

The relative accuracy of red cell folates is most different with Amersham. This kit gave the highest results. The use of sodium ascorbate instead of ascorbic acid distinguishes the haemolysate preparation of this kit from the others. At its pH both haemolysis and deconjugation will be incomplete, and conditions at the binding stage will favour affinity for polyglutamates if these are still present. The concentration of folate^{7 12} and the incubation time of the haemolysate^{7 12} affect the results with some kits. The estimation of red cell folate is of greater clinical value than that of serum folate¹³ and the need for a red cell folate standard is evident.

The Wellcome immunoassay quality control programme issued an advisory note concerning the higher vitamin B12 and serum folate results with the Becton Dickinson solid phase kit. Our results agree with it but show that it may not apply to the solid phase no-boil kit for vitamin B12 and red cell folates. Most manufacturers recommend that kit users should determine their own reference intervals, but differences in interpretation of some results with Becton Dickinson kits suggest that this is not universally done.

The results of IFA tests show that strong antibodies and normal sera are correctly diagnosed by all methods. The tests using commercial reagents are superior to the in-house procedures in the detection of weak antibodies. The method of Gottlieb *et al*,³ which does not allow for the effect of serum binding, gave the lowest incidence of positive results. We have not tested specificity.

Most laboratories undertake assessment of polymorph nuclear segmentation. The two trials we carried out show that there is appreciable discrepancy. There is evidently difficulty in deciding what may con-

Laboratory diagnosis of megaloblastic anaemia

stitute discrete lobes or what the reference range is, or both. At a subsequent meeting trial participants were asked to count the lobes of a nucleus shown in a projected transparency. The responses varied from three to eight, with two thirds agreeing on six lobes. Although not a specific finding for vitamin deficiency, hypersegmentation is of high sensitivity in patients with megaloblastic anaemia,¹⁴ and an increase in segmentation may occur with a fall in the serum vitamin B12 even before the dU suppression test becomes abnormal.¹⁵ The trials show that if the assessment is to be generally useful more familiarity with normal films and what constitutes an individual lobe seem to be required.

We thank Mr B Orton, Miss D Heap, and Mr P Shackleton for help with the organisation of the trials and the trial participants for their cooperation.

References

- 1 Dawson DW, Fish DI, Frew IDO, Orton B, Roome T. Vitamin B12 quality control trials. *Clin Lab Haematol* 1981;3:323-30.
- 2 Varley H, Gowenlock AH, Bell M. *Practical clinical biochemistry*. vol 1. 5th ed. London: Heinemann, 1980:301-2.
- 3 Gottlieb C, Lau K-S, Wasserman LR, Herbert V. Rapid charcoal assay for intrinsic factor (IF), gastric juice unsaturated B12 binding capacity, antibody to IF, and serum-unsaturated B12 binding capacity. *Blood* 1965;25:875-85.
- 4 Ardeman S, Chanarin I. Assay of gastric intrinsic factor in the diagnosis of Addisonian pernicious anaemia. *Br J Haematol* 1965;11:305-14.
- 5 Ghazi HA. Effect of serum vitamin B12 binding on intrinsic factor antibody detection in pernicious anaemia. *Acta Haematol* 1972;47:264-8.
- 6 Conn DA. Intrinsic factor antibody detection and quantitation. *Med Lab Sci* 1986;43:48-52.
- 7 Bain BJ, Wickramasinghe SN, Broom GN, Litwinczuk RA, Sims J. Assessment of the value of a competitive protein binding radioassay of folic acid in the detection of folic acid deficiency. *J Clin Pathol* 1984;37:888-94.
- 8 Raniolo E, Phillipou G, Paltridge G, Sage R E. Evaluation of a commercial radioassay for the simultaneous estimation of vitamin B12 and folate, with subsequent derivation of the normal reference range. *J Clin Pathol* 1984;37:1327-35.
- 9 Gilois CR, Beattie G, Mills SP. Measurement of vitamin B12 and serum folic acid: a comparison of methods. *Med Lab Sci* 1986;43:140-4.
- 10 Sheridan BL, Pearce L. Vitamin B12 assay compared by use of patients' sera with low vitamin B12 content. *Clin Chem* 1985;31:734-6.
- 11 International Committee for Standardization in Haematology. Proposed serum standard for human serum vitamin B12 assay. *Br J Haematol* 1986;64:809-11.
- 12 Shane B, Tamura T, Stokstad R. Folate assay: A comparison of radioassay and microbiological methods. *Clin Chim Acta* 1980;100:13-9.
- 13 Chanarin I. *The megaloblastic anaemias*. 2nd ed. Oxford: Blackwell Scientific Publications, 1979:194.
- 14 Lindenbaum J, North BJ. Megaloblastic anaemia and neutrophil hypersegmentation. *Br J Haematol* 1980;44:511-3.
- 15 Blundell EL, Matthews JH, Allen SM, Middleton AM, Morris JE, Wickramasinghe SN. Importance of low serum vitamin B12 and red cell folate concentrations in elderly hospital inpatients. *J Clin Pathol* 1985;38:1179-84.

Requests for reprints to: Dr DW Dawson, Consultant Haematologist, North Manchester General Hospital, Crumpsall, Manchester M8 6RB, England.